Boehringer Ingelheim Pharmaceuticals, Inc - Comment

Document ID: FDA-2005-D-0282-0009
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: April 25 2013, at 12:00 AM Eastern Daylight Time
Date Posted: April 26 2013, at 12:00 AM Eastern Standard Time
Comment Start Date: February 25 2013, at 12:00 AM Eastern Standard Time
Comment Due Date: April 26 2013, at 11:59 PM Eastern Standard Time
Tracking Number: 1jx-84z9-tb9d
View Document:

This is comment on Notice

See Attached

Title:
Boehringer Ingelheim Pharmaceuticals Inc Comment 2005-D-0282 HCV Letter

View Attachment:

Total: 2

GlaxoSmithKline - Comment
Public Submission Posted: 04/26/2013 ID: FDA-2005-D-0282-0008

Comment Period Closed
Apr 26,2013 11:59 PM ET

Boehringer Ingelheim Pharmaceuticals, Inc - Comment
Public Submission Posted: 04/26/2013 ID: FDA-2005-D-0282-0009

Comment Period Closed
Apr 26,2013 11:59 PM ET